Real-World Data Supporting Omnipod DASH® Insulin Management System for Improved Diabetes Management

Guest Blogger
Category: Optimisation

When making treatment decisions for type 1 diabetes (T1D), healthcare professionals increasingly rely on real-world data to understand how therapies perform outside of clinical trials. A recent study— Aleppo G et al. Diabetes Ther. 2023. 14:593–610—offers compelling, real-world evidence on the clinical value of Omnipod DASH, a tubeless insulin pump therapy designed to simplify daily care.

Real-World Evidence: Impact of Omnipod DASH on A1C Levels

- Aleppo trial (retrospective real-world study): Adults and paediatric participants transitioned from multiple daily injections (MDI) or subcutaneous insulin infusion (CSII) to Omnipod DASH and achieved a mean A1C reduction of 0.9% after three months.

Reduction in Patient Reported Hypoglycaemic Episodes with Omnipod DASH

- Aleppo trial: Weekly episodes <70 mg/dL dropped from 2.9 to 1.3 in adults and from 2.8 to 1.5 in paediatric users.

The reduction in low blood glucose events highlights the potential of Omnipod DASH to support safer day-to-day diabetes management, particularly in home and paediatric settings.

Insulin Usage Trends After Switching to Omnipod DASH

- Aleppo trial: Adults demonstrated a 19.9% decrease in total daily dose (TDD), reflecting effective insulin delivery without the need for dose escalation. TDD in the pediatric cohort, remained stable.*

Tracking insulin usage trends over time may inform dose adjustments.

Comparing Omnipod DASH with Traditional Insulin Management like Multiple Daily Injections

The Aleppo trial shows that transitioning patients from traditional insulin therapy, especially MDI, to the tubeless Omnipod DASH system led to better glycaemic control, and reduced insulin needs.3 These improvements support a more patient-centred approach to diabetes care, without the added burden of MDI.

Study Limitations and Real-World Data Interpretation

- Aleppo trial: The retrospective design and lack of a control group limits direct comparison and generalizability of results. Additionally, hypoglycemia rates were self-reported introducing potential recall bias.

Despite these limitations, this study offers valuable, practice-relevant insights into the performance of Omnipod DASH compared to MDI. 

Access the full Aleppo study: Treatment Satisfaction with Omnipod DASH in Adults with Type 1 Diabetes

 

Clinical Considerations: Who May Benefit Most from Omnipod DASH?

Omnipod DASH is approved for all individuals who require insulin therapy, making it a suitable option for both paediatric and adult populations.

Omnipod DASH may be particularly suitable for individuals who:

  • Are moving from injections and prefer a discreet, tubeless insulin delivery system
  • Need paediatric-compatible devices that support active lifestyles
  • Seek better glycaemic control and without complex setups
  • Experience high diabetes distress or pump fatigue

Frequently Asked Questions

How long can each Omnipod DASH Pod be worn?

Which rapid-acting insulins are compatible with Omnipod DASH Pods?

Is the Omnipod DASH Personal Diabetes Manager waterproof?

Can Omnipod DASH data integrate with telemedicine platforms?

What is the approved age range for Omnipod DASH use?

Omnipod DASH is a simple system with demonstrated clinical outcomes

To understand which of your patients could benefit most from Omnipod DASH, click the button below.
 

Review Patient Profiles
The Omnipod DASH Insulin Management System is intended for subcutaneous delivery of insulin at set and variable rates for the management of diabetes mellitus in persons requiring insulin. Additionally, the Omnipod DASH System is interoperable with a compatible blood glucose meter to receive and display blood glucose measurements. The Omnipod DASH System has been tested and found to be safe for use with the following U-100 insulin: NovoLog®, Humalog®, Apidra®, Fiasp®, Lyumjev®, or Admelog®. Refer to Omnipod DASH Insulin Management System User Guide and www.omnipod.com/safety for complete safety information including indications, contraindications, warnings, cautions, and instructions.

*In a large retrospective observational study of patient-reported outcomes of 4,738 people with T1D in the US before (baseline) and 90 days after (follow-up) initiation of the tubeless Omnipod DASH Insulin Management System , children, adolescents and adults who switched from MDI to Omnipod saw an improvement in HbA1c of -0.9% (8.6 to 7.7% for pediatric participants and 8.5% to 7.6% for adults); adults reduced TDD by -19.9% (62.3u to 49.8u); Pediatric self-reported hypoglycemia episodes/week improved - 1.3 (2.8 to 1.5) and adult hypoglycemia improved - 1.6 (2.9 to 1.3). All results had p-value <0.0001. Aleppo G et al. Diabetes Ther. (2023)